Received Oct 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 94kg2 | — |
Administration in less than recommended intervals; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 50-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 94kg2, expiry date 28-NOV-2027) for prophylaxis. Previously administered products included Boostrix (received first dose on 21-MAR-2025). On 30-SEP-2025, the patient received the 2nd dose of Boostrix. On 30-SEP-2025, 193 days after receiving Boostrix, the patient experienced drug dose administration interval too short (Verbatim: Administration in less than recommended intervals). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 02-OCT-2025 The reporter reported that administration of Boostrix in intervals that are less than 10 years. The reporter mentioned that the patient received the first dose on 21st March 2025 and the second dose on 30th September 2025. The patients initials, male and 50 years of age. The vaccine dose administered in September had a lot number of 94kg2 and expiration date 28th November 2027.